Executive Chairman David Schlanger Sells 13,998 Shares of Progyny Inc (PGNY)
Executive Chairman David Schlanger sold 13,998 shares of Progyny Inc (NASDAQ:PGNY) on January 2, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $37.58 per share, resulting in a total sale amount of $526,162.84.
Progyny Inc is a company that provides fertility and family building benefits solutions in the United States. It offers employers a benefits solution that includes both fertility and pharmacy benefits, and it supports patients through their entire fertility journey.
Over the past year, the insider has sold a total of 1,333,998 shares of Progyny Inc and has not made any purchases of the stock. The insider transaction history for Progyny Inc shows a pattern of 42 insider sells and no insider buys over the past year.
Progyny Inc's shares were trading at $37.58 on the day of the insider's recent sale, giving the company a market capitalization of $3.416 billion. The price-earnings ratio of the stock stands at 68.56, which is above the industry median of 26.635 but below the company's historical median price-earnings ratio.
According to the GuruFocus Value assessment, with a share price of $37.58 and a GF Value of $80.66, Progyny Inc has a price-to-GF-Value ratio of 0.47, indicating that the stock is significantly undervalued based on its GF Value.
The GF Value is calculated considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
